Overview
- Exact Sciences shareholders will receive $105 per share in cash, valuing the equity at about $21 billion and the transaction at roughly $23 billion including an estimated $1.8 billion of net debt.
- The companies expect to close in the second quarter of 2026, pending Exact shareholder and regulatory approvals, after unanimous approval by both boards.
- The acquisition adds Cologuard, Oncotype DX, and cutting-edge liquid-biopsy and molecular residual disease tests to Abbott’s diagnostics portfolio.
- Abbott projects Exact Sciences will generate more than $3 billion in revenue this year with high-teens organic growth, lifting combined diagnostics sales to over $12 billion annually after closing.
- Shares reacted to the announcement with Exact Sciences jumping and Abbott dipping in early trading, while Exact will maintain its Madison presence and CEO Kevin Conroy will serve in an advisory role post-close.